Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.30 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.30 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425387 | 0.94 | TK1 (0.33) | TK2CA12CA1CA2CA9 | |
| SCHEMBL4415442 | 0.93 | MAPT (0.34) | TK2CA12CA1CA2CA9 | |
| SCHEMBL4411449 | 0.91 | LMNA (0.33) | KDM4EMAPT | |
| SCHEMBL4419177 | 0.91 | CA12 (0.32) | TK2CA12CA1CA2CA9 | |
| SCHEMBL4414566 | 0.90 | CA12 (0.38) | TK2CA12CA1CA2CA9 | |
| SCHEMBL4412301 | 0.87 | KMT2A (0.33) | TK2CA12CA1CA2CA9 | |
| SCHEMBL4414797 | 0.86 | TK1 (0.37) | TK2CA12CA1CA2CA9 | |
| SCHEMBL4426611 | 0.84 | ALDH1A1 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL4421554 | 0.84 | SMN1; SMN2 (0.33) | KDM4EMAPT | |
| SCHEMBL4415959 | 0.83 | DDX3X (0.34) | TK2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651642-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-11-04 | — | — | EP | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| EP-1651642-A4 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2006-11-29 | — | — | EP | disclosed |
| EP-1651642-A1 | PNA MONOMER AND PRECURSOR | Panagene Inc. (KR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050026930-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009998-A1 | PNA MONOMER AND PRECURSOR | PANAGENE INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026930-A1 | PNA monomer and precursor | RNGTT, POLL, NSUN3 | TK2 2416/4885CA12 3059/4885CA1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.